anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain the subject preparation for treating vertigo and disorder of balance, simply being administered, making a patient easily take, having excellent prolonged action, comprising both betahistine, its salt or their mixture as an active ingredient and a base suitable for endermism. CONSTITUTION:An endermism preparation comprises betahistine, its salt or its mixture (especially isolation type has high absorption ratio) and a base suitable for endermism. The content of the active ingredient is preferably about 0.1-10wt.%. An absorption promoter is selected from N,N-diethyl-m-toluamide, a surfactant, laurocapram, isopropyl myristate, an alkyl-D-glucoside, an alkyl-/beta- D-thioglucoside, an L-alkylpyrrolidone, a terpene, phospholipid spherule and a phospholipid-cholesterol spherule and used. The preparation is used as a therapeutic agent for vertigo and disorder of balance such as for MeTniere disease, Metniere syndrome, dizziness, etc. The preparation is used in the dosage form of ointment, paste, cataplasm, etc.
EMS-whole-body-workouts are less time-consuming and effort-intensive but generate physical effects which are comparable to conventional strength training. Therefore EMS could lower the barrier to physical activity. The present study focusses on acute psychological effects of an EMS workout - especially with regard to the reduction of depressive symptoms. Physical activity is notably important for patients with depression and shows multiple positive psychological and physical effects. But due to disease-related factors like lethargy, physical activity is far too rarely implemented. Therefore EMS-whole-body-workouts could provide an opportunity to generate positive psychological effects through a less (subjective) cost-intense strength training.
PROBLEM TO BE SOLVED: To obtain a foundation for cosmetics, capable of controlling color tone of skin, exhibiting whitening and humidifying effects and having high safety by using a natural component extracted from a plant known as a Chinese medicine from ancient times. SOLUTION: This foundation for cosmetics is obtained by using an extraction component from KANZOU (Glycyrrhizae Radix) which is oil-soluble extract extracted from Glycyrrhiza glabra of a leguminous plant known as a Chinese medicine by ordinary method. In the foundation for cosmetics, proper amount of powder such as coloring pigment is blended with oil content, an emulsifier, a perfume, a thickener and other additives, etc., as components other than the active ingredient. Further, phospholipid such as lysolecithin and a thickener polymer such as quince seed are preferably added thereto in addition to the KANZOU extract ingredient. Refreshing touch feeling free from tackiness is given to users when the quince seed is used for foundation. The blend amount of the quince seed is about 5-10wt.%.  The effect for promoting percutaneous absorption of active ingredients is obtained by including the phospholipid therein.
BACKGROUND: Inflammation plays a crucial role in prostate cancer (PCa) progression and mortality. This study aimed to investigate the predictive value of the inflammatory burden index (IBI) and its components for mortality risk among men aged 40 years and older.
METHODS: A total of 7,344 participants from the NHANES 2001-2010 were included. High PCa risk was defined as a %fPSA greater than 25% and a tPSA level less than 4.0 ng/mL. Cox regression and logistic regression analyses were conducted to assess the association between IBI, PCa risk, and mortality. Receiver operating characteristic (ROC) curve analysis and random survival forest (RSF) model were utilized to evaluate the predictive value of IBI and its components for mortality.
RESULTS: Elevated IBI levels were significantly associated with an increased risk of all-cause mortality (HR = 1.08 [1.05-1.10]) and cancer mortality (HR = 1.11 [1.07-1.15]). High-risk PCa cases also exhibited elevated mortality risk (all-cause: HR = 1.35 [1.19-1.54]; cancer: HR = 1.65 [1.27-2.14]). Additionally, the combined effect of elevated IBI levels and high PCa risk showed a synergistic impact on mortality outcomes (all-cause: HR = 1.49 [1.27-1.74]; cancer: HR = 1.76 [1.29-2.40]). ROC curve analysis revealed that IBI had the highest AUC for predicting all-cause mortality (AUC = 0.690 at 3 years, 0.622 at 5 years, 0.634 at 10 years, and 0.632 at 15 years) compared to its individual components (CRP, NEU, LYM). RSF analysis highlighted IBI as the most significant predictor of all-cause and cancer mortality.
CONCLUSION: The combined effect of elevated IBI levels and high PCa risk demonstrated a synergistic impact on increased mortality risk among men aged 40 years and older. IBI demonstrated superior predictive performance for mortality outcomes compared to individual inflammatory markers. These findings underscore the potential utility of IBI as a prognostic biomarker for mortality risk assessment in individual with high PCa risk.
Participants will receive rituximab + placebo. Following confirmation of iNHL disease progression by the independent review committee and unblinding, participants may be eligible to receive open-label idelalisib 150 mg twice daily.
As an increasing percentage of preterm infants survive worldwide, the number of infants at risk for retinopathy of prematurity (ROP) is increasing. These infants are also at high risk for future abnormal visual function and neurodevelopment. While current screening approaches address identifying eyes for treatment of severe ROP, there are no attempts to address the later subnormal vision of many preterm infants. In part, this is due to a lack of information about the retina beyond that of retinal vascular development. In addition, the most common method to screen for ROP remains indirect ophthalmoscopic examination by physicians with annotated drawings for documentation, a method proven to be poorly reproducible and stressful to the fragile infant. Bedside retinal photographs enable documentation and the possibility for telemedicine approaches, but lack information about retinal microanatomy, are poor quality in darkly pigmented eyes and also are stressful to the infant because of the required light exposure. We need an infant-friendly, more practical approach to evaluate ROP efficiently and additional information about ocular and neurovascular development that could lead to improved clinical care.

This research builds on our group's ability to reliably capture and process non-contact, infrared optical coherence tomography (OCT) and OCT-angiography of retinal microanatomy and microvasculature at high speed, across a wide field of view, and at the bedside in preterm infants. Our overall objectives are threefold: first, to evaluate infant microanatomy and microvascular flow findings relevant to vision and neurodevelopmental outcomes in children; second, to translate and test our imaging achievements for real-world use by nurses at the bedside and for better clinical insight and feedback; and third, to gather additional data in eyes that progress to treatment and dive deeper into the insight that they provide into pathways of disease in ROP. The investigational OCT imaging will be used in this research to gather information that is otherwise not accessible to the physician. This research will lay the groundwork for future use of infant OCT markers to guide care.
The invention relates to the field of molecular vaccinology, and provides a method for improving the antigen immunogenicity/antigen trimer stability of an SARS-CoV-2 mutant strain ECD and an SARS-CoV-2 mutant strain ECD immunogenic protein/peptide with improved immunogenicity/antigen trimer stability. Including but not limited to the extracellular domain (ECD) of the spike protein (S protein) of SARS-CoV-2 strain, B.1 strain, B.1.1.7 strain or B.1.351 strain with the genome sequence number GenBank Accession No. MN908947.3, the ECD antigen immunogenicity/antigen trimer stability is improved by introducing the homotrimer formed by the mutation site and the trimerization auxiliary structure. The vaccine further comprises a pharmaceutically acceptable adjuvant. The vaccine combination shows excellent immunogenicity in mice and cynomolgus monkeys, and can maintain humoral immunity and cellular immune response for a long time. The recombinant trimeric protein vaccine can be used for preventing SARS-CoV-2 infection related diseases.
The research evaluated the effect of nutrition and fluid restriction training on interdialytic fluid intake and intradialytic hypotension in hemodialysis patients. The study sample, conducted with an experimental design, consisted of 71 patients (36 experimental and 35 control) who received dialysis treatment in a private dialysis centre affiliated with the Istanbul Provincial Health Directorate. Fluid Control Scale in Hemodialysis Patients (HHSÖ), Blood Pressure Control Form, Bioimpedance Analysis, Bioimpedance Analysis Compliance Form, Things to Consider Before Bioimpedance Analysis, and Nutrition Booklet for Dialysis Patients were used to collect the data. Parametric methods were used to analyze the data. Differences between the proportions of categorical variables in independent groups were analyzed with Chi-Square and Fisher's exact tests. The t-test was used to compare quantitative continuous data between two independent groups. A dependent group t-test was used to compare intra-group measurements.

After randomization of the experimental and control groups, both groups were measured with the BCM (Fresenius Medical Care Body Composition Monitor) device. The experimental group was given face-to-face fluid restriction training in line with the Nutrition Booklet for Dialysis Patients. At the end of the second month, BCM was measured again in both groups. During the follow-up of the experimental group, training was repeated according to the needs of the patients.
NEW MATERIAL:A compound expressed by formula I (R1 to R3 represent lower alkyl; R4 represents H or lower alkyl; R5 represents H, cation or lower alkyl; n is 0-5) and an optical isomer thereof. EXAMPLE:2-(p-Trimethylsilylmethylphenyl)propionic acid. USE:An anti-inflammatory, analgesic antithermic agents. PREPARATION:An aralkyltrimethylsilane expressed by formula II is used as a starting substance, which is converted into an aralkylalkyl ketone derivative expressed by formula III with an acid chloride. Then the compound is converted into a lithium cyanide compound by adding acetocyanohydrine in the presence of lithium hydride. A dialkyl or aryl cyanophesphonate is added to convert the lithium cyanide compound into a phosphonate compound expressed by formula IV (R is alkyl or aryl), which is then reduced in the presence or Pd-C to afford a cyano derivative expressed by formula V, which is subsequently hydrolyzed.
The goal of asthma guideline therapy is to achieve disease control, by minimizing impairment and decreasing the risk of exacerbations and adverse effects of the disease and its treatment. The primary objective of most clinical trials of biologics for severe asthma is a reduction in exacerbation rate. Recently, studies with patients at the lower guideline steps have also selected exacerbation reduction as a primary objective. These trials in patients with milder disease frequently demonstrate statistically significantly fewer exacerbations, but their power calculations reflect larger sample size and smaller effect size. Exacerbations have a precise consensus definition, although a minimal clinically important difference has not been established. Reduction of exacerbations in severe asthma is commonly 10-fold greater than in mild disease. Further, reduction in exacerbations is not always associated with reduced impairment. If superior control is the objective, both domains should demonstrate consistent and parallel improvement. The disconnect may reflect the need for alternative tools for measurement of impairment or, possibly, different therapeutic mechanisms of action. Determining response to biologics or discussion of disease remission requires assessing symptoms that may occur daily rather than focusing on exacerbations that occur once or twice a year for patients at the highest steps of care according to the guidelines.
Cardiovascular diseases are the leading cause of death worldwide, and arterial hypertension is a recognized cardiovascular risk factor that is responsible for high morbidity and mortality. Arterial hypertension is the result of an inflammatory process that results in the remodeling and thickening of the vascular walls, which is associated with an immunological response. Previous studies have attempted to demonstrate the relationship between oral disease, inflammation, and the development of systemic diseases. Currently, the existence of an association between periodontitis and hypertension is a controversial issue because the underlying pathophysiological processes and inflammatory mechanisms common to both diseases are unknown. This is due to the fact that periodontitis is a chronic inflammatory disease that affects the interface of teeth and surrounding tissues. However, the most likely explanation for understanding this association is related to low-grade chronic inflammation. An initial path in the study of the relationship between the mentioned pathologies is the possibility of an epigenetic influence, mediated by noncoding RNAs as microRNAs. Thus, in the present review we describe the role of microRNAs related to arterial hypertension and/or periodontitis. In addition, we identified 13 common microRNAs between periodontitis and hypertension. According to the predictions of the DIANA-mirPath program, they can regulate genes involved in 52 signaling pathways.
Pathological Skin Picking (PSP) is one of many debilitating Body Focused Repetitive Behaviors (BFRBs) that involves repetitive picking to gain the gratification of relieving anxiety or tension. Thus, this behavior may cause infections, lesions, and scarring, resulting in psychosocial impairment or medical attention. Because of the habitual/compulsive nature of the disorder, researchers conceptualize this maladaptive coping mechanism as a behavioral addiction which may occur without conscious awareness. Therefore, it is important to identify the automatic motivational orientations behind BFRBs. There is compelling evidence to suggest that a novel technological behavior paradigm, called Approach Avoidance Training (AAT), can be used to assess and modify action tendencies (i.e., approach or avoidance) in behavioral addictions like PSP. This game-like task has the participant push (=avoid) or pull (=approach) a joystick based on a target and control stimulus presented on a computer screen. This push-pull paradigm is in response to the individual's inherent action tendencies.

The overarching goal is to determine effective principles of change in interventions for BFRBs. Therefore, assessing neurocognitive components using computer-based training programs can help identify the implicit processes underlying the disorder. The objective of the study is to examine the feasibility of using AAT to modify PSP action tendencies, and potentially improve PSP symptoms. The investigators predict that individuals with PSP will have a pathological approach tendency towards skin as measured by the Approach-Avoidance Assessment (AAA). Therefore, AAT will promote reduction of approach to skin stimuli. To retrain one's action tendencies the investigators will randomize participants to the following training conditions: Avoidance Training (AvT; avoidance of skin stimuli), Approach Training (ApT; approach skin stimuli), or Placebo Training (PT; equal approach/avoidance of skin stimuli). The investigators will also administer an eye-tracking task to assess visual gaze response to pictures of irregular skin and neutral stimuli to evaluate training-induced changes in action tendencies. Previous studies have shown the AAT's success in reducing action tendencies and symptoms in other addictions like problematic alcohol use and cigarette smoking Therefore, AAT may prove effective in modifying the behavioral addiction of PSP. Sixty adults with PSP will be randomly assigned to (a) approach training (b) avoidance training or (c) placebo training. All participants will then be sent a follow-up survey approximately two weeks after completion of the main study to determine changes in symptoms. This pilot study is expected to guide the development of an accessible, cost-efficient, and effective cognitive training programs for individuals with PSP.
The present invention relates to a pharmaceutical composition for preventing or treating hyperphosphatemia in chronic kidney diseases and a functional health food for alleviating hyperphosphatemia in chronic kidney diseases, using Lactobacillus sp. KCCM 11826P strain which is highly capable of absorbing phosphate. According to the present invention, the Lactobacillus sp. KCCM 11826P selected in the present invention has an excellent phosphorus absorption capacity, and can thus effectively inhibit phosphorus absorption into the human body. Also, the present invention can replace conventional calcium-based phosphorus binders and minimize the side effects thereof caused by an increase in the concentration of calcium in blood and thus, can effectively prevent or treat hyperphosphatemia and complications of kidney diseases. Also, the Lactobacillus sp. KCCM 11826P selected in the present invention can be taken far more inexpensively than the conventional phosphorus binders, and the characteristics of the strain allows the present invention to be developed as a yogurt, powder, or healthy meal for patients and the like, and can thus be made much easier to ingest than conventional phosphorus binders.
Agent for use against the AIDS virus and cancer contains, as active ingredients, polysaccharides extracted from the husks of nuts of the genera Juglans or Carya (Juglandaceae) with an aq.  alkali soln. Pref., the dried husks are milled fine and extracted with aq. alkali soln. Then an acceptable acid (e.g. acetic acid) is added to neutralise the mixt. and salts removed by dialysis, simultaneously with centrifuging to ppte. or separate the extracted substances. Solids were filtered off and freeze-dried to recover a powdered extract. USE/ADVANTAGE - These extracts inhibit HIV in vitro at a concn.  of 64-512 microg/ml and have carcinostatic activity against e.g. Sarcoma 180 cells.
Idiopathic pulmonary fibrosis is a progressive and lethal interstitial lung disease with an unclear etiology and limited treatment options. Fatty acid synthase (FASN) plays various roles in metabolic-related diseases. This study demonstrates that FASN expression is increased in fibroblasts from the lung tissues of patients with idiopathic pulmonary fibrosis and in bleomycin-treated mice. In MRC-5 cells, the inhibition of FASN using shRNA or the pharmacological inhibitor C75 resulted in the increased mRNA and protein expression of glycogen synthase kinase 3β and Axin1, both negative regulators of the Wnt/β-catenin signaling pathway, and promoted autophagy. This outcome led to a decrease in β-catenin protein and mRNA levels, effectively inhibiting the proliferation, migration, and differentiation of lung fibroblasts into myofibroblasts, while inducing the differentiation of fibroblasts into adipofibroblasts. In vivo experiments showed that C75 alleviated bleomycin-induced lung fibrosis in mice by inhibiting β-catenin. In conclusion, these findings suggest that inhibiting FASN in fibroblasts may diminish the activity of the Wnt/β-catenin signaling pathway, providing a potential therapeutic avenue for pulmonary fibrosis.
AIMS: The probiotic bacterium Levilactobacillus brevis (L. brevis) has been proposed as a potential solution to manage mood disorders and alleviate stress-related sleep disturbances. However, the underlying mechanisms of its effects have not been fully elucidated. The aim of this study was to explore the impact and potential mechanisms of L. brevis SG031 supplementation on anxiety/depression-like behaviors and stress-induced changes in sleep patterns and sleep-related autonomic function.
MAIN METHODS: Male Wistar-Kyoto rats were administered low, medium, or high doses of L. brevis SG031 or a vehicle for 4 weeks, followed by behavioral tests to evaluate anxiety and depression. After an additional 2 weeks of SG031 or vehicle administration, a cage-exchange paradigm was performed with 24-hour physiological signal measurements under different stress conditions. Fecal samples were collected to construct a 16S rRNA library and assess fecal short-chain fatty acids (SCFAs).
KEY FINDINGS: High-dose SG031 administration yielded reduced depression-like responses and enhanced social interaction in behavioral tests. It also exhibited a protective effect against stress-induced sleep disturbance characterized by decreased sleep time, increased awake time, and autonomic dysfunction during sleep. Fecal examination indicated that high-dose SG031 administration exerted beneficial effects on gut health by maintaining the gut microbial abundance, preserving stability of the microbial composition, and enriching the gut with SCFAs, which were associated with improvements in sleep and autonomic function.
SIGNIFICANCE: These findings collectively underscore the multifaceted potential of SG031 in addressing mental health and stress-related sleep challenges through the modulation of the gut microbiota.
PURPOSE:To obtain an anti-inflammatory analgesic agent for external use free from systemic side effects such as gastrointestinal disorder, by using 2-(2- fluoro-4-biphenylyl)propionic acid as an active component and combining the compound with an oleophilic base. CONSTITUTION:2-(2-Fluoro-4-biphenylyl)propionic acid of formula is used as an active component and is compounded with an oleophilic base such as petrolatum, liquid paraffin, natural rubber, synthetic rubber and polybutene. Preferably, the active component is used in combination with a transcutaneous absorbefacient (e.g. terpene such as peppermint oil and eucalyptus oil or higher fatty acid ester such as isopropyl myristate). The absorption of the active compound through the skin can be improved by the use of the transcutaneous absorbefacient. When the agent is used in the form of ointment, plaster, solution, etc., the drug is continuously released from the agent, absorbed through the skin in high efficiency and selectively transferred to the inflamed site to exhibit the activity.
People struggling with depression are burdened by losses they can't and won't accept. They find themselves at odds not only with their circumstances, but also with symptomatic expressions of their exhausting efforts to shelter from, gird against, and contend with their pain and desolation. Their embattled sense of self gets no respite: Everything, including the depression itself, feels threatening, a violation, other. This article investigates why, and demonstrates how, hypnosis is particularly well suited for treating such self-referential, adversarial entanglements. Fundamentally associational in both structure and function, hypnosis resonates with other long-established, connection-based traditions for altering suffering. In keeping with Taoist, Sufi, and Buddhist ideas and practices, hypnosis introduces a quality of acceptance into the relationship between self and other, between self and pain. Clinical hypnosis establishes and maintains a context of interpersonal and intrapersonal security, a protective space and a relationship in which avolitional experience is not felt to be out-of-control or uncontrollable, but rather not-in-need-of-being-controlled. It thus becomes safe for clients to become curious about, approach, and engage with what in other settings would have the potential of producing a fearful, even panicky, reaction. By altering the boundary between clients and their suffering, clinicians facilitate an effortless rapprochement, making possible the shifting, repurposing, and unraveling of symptoms.